Market Outlook Snapshot Market Dynamics Regional Forecast Country Insights Segment Analysis Competitive Landscape Industry News report.faq_name
On This Report

Blood Testing Market Size & Growth Forecast 2027–2036, By Segments (Method, Product, End-use, Test Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Report ID: FBI 7337| Published Date: Sep-2026| Format: PDF, Excel
MARKET OUTLOOK

Market Size and Growoth Outlook

Blood Testing Market size was worth USD 91.96 Billion in 2026 and is expected to grow at 7.84% CAGR between 2027 and 2036, attaining USD 195.61 Billion by 2036. The industry revenue for 2027 is calculated at USD 98.08 Billion.

Base Year Value (2025)
USD 89.55 Billion
CAGR (2026-2035)
6.8%
Forecast Year Value (2035)
USD 172.89 Billion
Historical Data Period
2021-2025
Largest Region
North America
Forecast Period
2026-2035

Get more details on this report

Request Free Sample Report
SNAPSHOT

Blood Testing Market Intelligence Snapshot

Regional Market Dynamics

Segment Momentum

Market Expansion Drivers

Leading Market Participants

FORECAST SNAPSHOT

Global Market Forecast Snapshot

Market Outlook

Regional and Segment Outlook

MARKET DYNAMICS

Market Growth Drivers and Industry Trends

Growing chronic disease burden driving routine diagnostic blood testing demand globally

The rising prevalence of chronic illnesses has made regular laboratory monitoring an essential component of long-term patient care, and this trend will propel the blood testing market growth across healthcare systems. Blood tests are routinely used to detect diseases, monitor treatment response, evaluate organ function, and identify complications before symptoms worsen. As healthcare providers place greater emphasis on early diagnosis and continuous disease management, demand for reliable and repeat diagnostic testing continues to expand across hospitals, diagnostic laboratories, and outpatient care settings.

Expansion of point-of-care testing centers improving decentralized diagnostic accessibility

Improved access to decentralized healthcare services is transforming diagnostic delivery, with the blood testing market gaining momentum as point-of-care testing centers become more widely available. These facilities enable faster clinical decision-making by providing timely test results closer to patients, reducing dependence on centralized laboratories and shortening turnaround times. Their growing presence supports healthcare delivery in community clinics, emergency care environments, and underserved regions where immediate diagnostic information is critical for effective patient management.

Increasing healthcare expenditure enabling adoption of advanced automated blood testing platforms

Higher investment in healthcare infrastructure is encouraging laboratories and medical institutions to modernize diagnostic capabilities, which will boost the blood testing market demand for automated testing platforms. Advanced laboratory systems improve workflow efficiency, reduce manual intervention, and enhance consistency in sample processing while supporting higher testing volumes. Healthcare providers are increasingly adopting automation to strengthen diagnostic accuracy, optimize laboratory operations, and address growing demand for routine as well as specialized blood analyses.

Growth Driver Impact on CAGR Regulatory Influence Geographic Relevance Adoption Rate Impact Timeline
Growing chronic disease burden driving routine diagnostic blood testing demand globally 2% High North America, Europe High Near Term
Expansion of point-of-care testing centers improving decentralized diagnostic accessibility 1.8% High Asia Pacific, North America High Mid Term
Increasing healthcare expenditure enabling adoption of advanced automated blood testing platforms 1.6% High Europe, North America High Mid Term
CUSTOM RESEARCH

Unlock insights tailored to your business with our bespoke market research solutions.

Click to get your customized report now.

Request Customization →
REGIONAL FORECAST

Regional Demand Dynamics

Polymer Modified Bitumen Market
Largest Region
North America
Largest Market Share in 2026

North America (Largest Region)

In the blood testing market, North America held the largest share in 2026, supported by advanced diagnostic infrastructure, high utilization of laboratory services, and strong demand for early disease detection and routine health screening. The region's well-established healthcare systems facilitate widespread use of blood-based diagnostics across hospitals, clinics, laboratories, and preventive healthcare programs. Increasing emphasis on monitoring chronic conditions, personalized treatment decisions, and timely diagnosis is also contributing to sustained demand for comprehensive blood testing services and technologies.

Asia Pacific (Fastest-Growing Region)

Asia Pacific is anticipated to register the fastest growth, fueled by expanding healthcare infrastructure, increasing awareness of preventive diagnostics, and rising demand for accessible testing services. Improvements in laboratory capabilities and healthcare delivery are enabling broader adoption of blood testing across both urban and developing healthcare markets. The growing prevalence of chronic diseases, increasing focus on early detection, and expansion of diagnostic services are encouraging healthcare providers to strengthen testing capacity, while technological advances are helping improve the accessibility and efficiency of blood-based diagnostics.

Parameter North America Asia Pacific Europe Latin America MEA
Innovation Hub i Scale Nascent Developing Advanced
Cost-Sensitive Region i Scale Low Medium High
Regulatory Environment i Scale Restrictive Neutral Supportive
Demand Drivers i Scale Weak Moderate Strong
Development Stage i Scale Emerging Developing Developed
Adoption Rate i Scale Low Medium High
New Entrants / Startups i Scale Sparse Moderate Dense
Macro Indicators i Scale Weak Stable Strong
COUNTRY INSIGHTS

Key Country Insights

United States 🇺🇸

Precision Diagnostics Adoption

The U.S. blood testing market emphasizes advanced diagnostic platforms, preventive screening, and integration with digital healthcare systems. Laboratories and healthcare providers continue expanding high-value testing services that improve clinical decision-making and operational efficiency.

Germany 🇩🇪

Laboratory Quality Focus

Germany prioritizes standardized laboratory workflows and high-accuracy blood testing supported by strong clinical quality requirements. Healthcare institutions increasingly adopt automated testing technologies that enhance consistency while addressing growing diagnostic demand.

Japan 🇯🇵

Preventive Healthcare Integration

Japan continues strengthening blood testing through preventive healthcare programs and routine health examinations. Clinical laboratories focus on efficient testing processes and reliable diagnostic performance to support an aging population and long-term disease management.

South Korea 🇰🇷

Digital Laboratory Expansion

South Korea advances blood testing through digitally connected laboratories and modern diagnostic infrastructure. Healthcare providers increasingly implement automated testing solutions that improve turnaround times and support broader access to precision diagnostics.

France 🇫🇷

Clinical Screening Enhancement

France continues expanding blood testing within preventive care and hospital-based diagnostics. The country prioritizes reliable laboratory services and efficient testing workflows to strengthen disease detection and improve patient management across healthcare settings.

Italy 🇮🇹

Hospital Testing Modernization

Italy focuses on modernizing hospital laboratories and expanding access to accurate blood testing services. Investments in automation and workflow optimization support improved diagnostic efficiency while meeting growing demand for routine and specialized testing.

SEGMENT ANALYSIS

Segment Leadership and Growth Trends

Blood Testing Market Share (%), Method, 2025

Automated
Manual

Go beyond the chart, access full insights & data tables

Request Free Sample Report

Method Segment Analysis: Automated (Largest & Fastest-Growing Segment)

The blood testing market was dominated by the automated method segment, which accounted for 68.45% in 2026 while also emerging as the fastest-growing segment. Automated testing systems are widely adopted because they deliver high-throughput processing, improved analytical accuracy, and standardized results while minimizing manual intervention and the risk of human error. Healthcare providers and diagnostic laboratories increasingly rely on automation to handle growing testing volumes, reduce turnaround times, and optimize laboratory workflows. Continued advancements in laboratory automation, integration with digital information systems, and demand for efficient diagnostic services are expected to reinforce the segment’s leadership.

Product Segment Analysis: Reagents & Kits (Largest Segment) vs Instruments (Fastest-Growing Segment)

The reagents & kits segment held the largest share of 62.33% in 2026, supported by their recurring use across routine diagnostics, disease screening, and specialized blood analyses. Since reagents and kits are consumed with every test performed, they generate sustained demand from hospitals, diagnostic laboratories, and blood banks. Ongoing expansion of preventive healthcare programs and increasing utilization of laboratory testing continue to strengthen the segment's dominant position.

The blood testing market is witnessing the fastest expansion in the instruments segment as healthcare facilities continue investing in advanced analyzers and integrated diagnostic platforms. Modern instruments improve testing efficiency, enhance analytical precision, and support higher sample throughput, enabling laboratories to meet rising diagnostic demands. Continuous technological innovation and the growing need for automated laboratory infrastructure are expected to accelerate adoption of advanced blood testing instruments.

End-use Segment Analysis: Hospitals (Largest & Fastest-Growing Segment)

Hospitals represented the largest end-use segment, capturing 50.03% in 2026, while also registering the fastest growth in the blood testing market. Hospitals conduct a broad range of diagnostic tests for emergency care, inpatient treatment, surgical procedures, chronic disease management, and routine health assessments, creating consistent demand for blood testing services. Their comprehensive laboratory capabilities, access to advanced diagnostic technologies, and increasing patient admissions support sustained utilization of blood testing solutions. Growing emphasis on early disease detection and integrated clinical diagnostics further reinforces hospitals' leading position within the market.

Segment Sub-Segment Largest Segment Fastest Growing
Test Type Complete Blood Count Test, Blood Glucose Test, Heart Test, Infectious Disease Screening, Kidney Test - Renal Profile, Cholesterol Test - Lipid Profile Test, Cancer Test, Urine Test, Antibodies Test – Rheumatoid Factor, Others
Product Reagents & Kits, Instruments, Software
Method Automated, Manual
End-use Hospitals, Pathology Labs, Blood Banks, Diagnostic Centers, Others
Competitive Landscape

Competitive Landscape and Market Positioning

Leading companies in the blood testing market:

  1. F. Hoffmann-La Roche AG (Switzerland)
  2. Abbott Laboratories (United States)
  3. Siemens Healthineers AG (Germany)
  4. Danaher Corporation (United States)
  5. Becton Dickinson and Company (United States)
  6. bioMérieux SA (France)
  7. Thermo Fisher Scientific, Inc. (United States)
  8. Bio-Rad Laboratories, Inc. (United States)
  9. Grifols S.A. (Spain)
  10. Sysmex Corporation (Japan)

Advances in diagnostic science are redefining competition as laboratories, testing service providers, and technology developers seek to deliver broader clinical insights from increasingly efficient testing workflows. Market participants are expanding beyond routine diagnostics by integrating molecular techniques, automation, and digital interpretation capabilities that improve clinical decision-making while supporting faster turnaround times. At the same time, the ability to address preventive healthcare, chronic disease management, and decentralized testing environments is becoming an important differentiator, encouraging continuous refinement of testing platforms, laboratory integration, and service quality across diverse healthcare settings.

Company Market Share Company Revenue Revenue CAGR (%) Product Portfolio Geographic Presence Innovation / R&D Focus Strategic Developments
No companies available.
🔒 This section is available as a standalone purchase. Buy only the data you need. Inquire Before Buying
Industry News

Industry Development/News

Company Name Date Key Development
Truvian Dec-25 Truvian achieved FDA clearance for its benchtop blood-testing system. This regulatory milestone is a critical step for the company's commercial scalability, setting the stage for a broader market rollout as it continues to pursue additional clearances for its comprehensive blood panel diagnostic menu.
Abbott Nov-25 Abbott acquired Exact Sciences for $21 billion, a major consolidation move positioning Abbott as a leader in cancer diagnostics. The transaction integrates Exact Sciences' portfolio, including the Cancerguard multi-cancer early detection blood test, significantly expanding Abbott's operational footprint and competitive capabilities in advanced molecular oncology and liquid biopsy screening.
Roche Nov-25 Roche executed a $200 million licensing agreement and a $75 million equity investment in Freenome. This strategic partnership focuses on developing and commercializing blood-based cancer screening tests outside the U.S., signaling a major expansion effort for Roche’s oncology diagnostic portfolio through high-value external technology integration.
Sonic Healthcare USA Nov-25 Sonic Healthcare USA acquired Cairo Diagnostics while simultaneously relocating its U.S. headquarters to Dallas. This dual action enhances the company's regional operational infrastructure and expands its diagnostic service capacity, specifically strengthening its portfolio in advanced cancer-related blood testing and diagnostic support services.
Function Health May-25 Function Health acquired full-body MRI company Ezra, significantly broadening its preventive health diagnostic offerings. By integrating advanced imaging services with its existing blood testing platform, the company is positioning itself to capture a larger share of the integrated consumer health monitoring market.
BD Jan-25 BD expanded its strategic collaboration with Babson Diagnostics to deploy fingertip blood collection technology across urgent care and physician office networks. This initiative represents a material shift in point-of-care operations, enhancing clinical access to minimally invasive blood testing in decentralized settings.
QIAGEN Sep-24 QIAGEN launched a new digital PCR system specifically designed for oncology clinical testing. The system enables high-precision DNA and RNA quantification, enhancing the technical capabilities for liquid biopsy and cancer monitoring, which are central to the evolution of the clinical blood diagnostics market.
Werfen Jul-24 Werfen introduced the GEM Premier 7000 with iQM3, the first point-of-care blood gas testing system featuring integrated hemolysis detection. This launch represents a material technological upgrade in critical care diagnostics, providing improved accuracy and operational efficiency in high-acuity blood analysis settings.
Abbott Apr-24 Abbott secured FDA clearance for its i-STAT TBI whole blood rapid test cartridge, developed in collaboration with the U.S. Army. This innovation significantly advances point-of-care diagnostic capabilities for traumatic brain injury, demonstrating the commercialization of new, high-utility blood-based testing technologies in critical care environments.
Veracyte Jan-24 Veracyte acquired C2i Genomics in a deal valued at up to $95 million. This acquisition bolsters Veracyte’s genomic testing capabilities and strengthens its competitive positioning in the blood-based cancer diagnostics segment by integrating specialized liquid biopsy and molecular monitoring technologies into its commercial product portfolio.
Report Customization

Explore This Report

Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.

1 report.custom report.segments 2 Custom TOC 3 Related Reports

Blood Testing Market — Custom Segments

Segment Sub-Segment
No segment data available.

Blood Testing Market — report.custom

Custom Chapter Custom Details
No custom TOC data available.

Need a different cut of the data?

Request Custom Research
report.faq_name

How big is the blood testing market?

In 2027 the market for blood testing is valued at USD 98.08 Billion.

How will the blood testing industry grow in terms of size and CAGR by 2035?

Blood Testing Market size was worth USD 91.96 Billion in 2026 and is expected to grow at 7.84% CAGR between 2027 and 2036, attaining USD 195.61 Billion by 2036.

How is decentralized healthcare influencing the blood testing market?

The expansion of point-of-care testing centers is improving access to rapid diagnostics, enabling faster clinical decisions while reducing dependence on centralized laboratories across diverse healthcare settings.

Why are healthcare providers investing in automated blood testing platforms?

Higher healthcare spending is supporting laboratory modernization through automated systems that improve workflow efficiency, enhance sample processing consistency, and accommodate growing routine and specialized testing volumes.

Why is the automated method the leading segment in the blood testing market?

Automated testing held a 68.45% market share in 2026 and is the fastest-growing method because it delivers high-throughput processing, greater analytical accuracy, standardized results, and improved laboratory efficiency.

What is driving the rapid growth of blood testing instruments?

Instruments are the fastest-growing product segment as healthcare facilities invest in advanced analyzers and integrated diagnostic platforms to improve testing precision, increase throughput, and support expanding laboratory automation.

Why does North America hold the largest share of the blood testing market?

North America leads through advanced diagnostic infrastructure, high laboratory utilization, and strong demand for early detection, routine screening, and chronic disease monitoring.

How is Asia Pacific accelerating blood testing market growth?

Asia Pacific is growing fastest as healthcare infrastructure, laboratory capabilities, preventive diagnostics, and access to blood testing services expand.

Who are the major participants shaping the blood testing landscape?

Major players in the blood testing market include F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (United States), Siemens Healthineers AG (Germany), Danaher Corporation (United States), Becton, Dickinson and Company (United States), bioMérieux SA (France), Thermo Fisher Scientific Inc. (United States), Bio-Rad Laboratories, Inc. (United States), Grifols S.A. (Spain), Sysmex Corporation (Japan)
Testimonials

Our Clients

"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."

Quality Assurance Manager

"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."

R&D Manager

"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."

Senior Marketing Manager
THE RESEARCH BEHIND THIS REPORT

Our Research Team & Methodology

Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.

THIS REPORT'S RESEARCH VERTICAL

Research Team Overview

♢
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.

Prepared by the Healthcare & Medical Devices Research Team

10+
Industry Verticals
100+
Countries Analyzed
5–7
Days Standard
Delivery
12k+
Research Reports
Published
On-
Demand
Customized Research
Available
6
Months Analyst
Support
PDF + XLS
Report Deliverables

Trust & Compliance

☷D&B D-U-N-S
♢GDPR & CCPA Compliant
♙ISO 9001 Certified (ISO 9001:2015)
♙SSL Encryption
▭Secure Payments
✓Confidential Handling

Research Domains

10 coverage areas
Medical Devices & Equipment Diagnostic Imaging Clinical Diagnostics Digital Health & Telemedicine Patient Monitoring Systems Surgical & Minimally Invasive Technologies Healthcare IT & Data Systems Biotechnology & Life Sciences Pharmaceutical Technologies Healthcare Delivery & Services

Research Intelligence

Executive Leadership
Product & Technology Experts
Manufacturing & Operations Leaders
Procurement & Supply Chain Professionals
Sales & Commercial Executives
Channel Partners & Distribution Networks
Enterprise Buyers & End Users
Industry Consultants & Regulatory Experts

Research Workflow & Quality Assurance

📥
01

Data Collection

Verified information gathered through primary and secondary research.

🔍
02

Data Triangulation

Cross-validation using multiple independent data sources.

📈
03

Forecast Modelling

Market estimates developed using historical trends and analytical models.

👨‍💼
04

Analyst Validation

Findings reviewed by domain experts for accuracy and consistency.

📝
05

Editorial & Quality Review

Final editorial, quality, and compliance checks before publication.

✅
06

Final Publication

Released after successful completion of the internal review process.

Report Coverage

📊 Market Assessment

  • Market Size & Forecast
  • Market Segmentation
  • Regional Analysis
  • Growth Drivers & Challenges
  • Market Dynamics

🏢 Competitive Intelligence

  • Competitive Landscape
  • Company Profiles
  • Competitive Benchmarking
  • Mergers & Acquisitions
  • Market Share Analysis or Key Company Strategies

🔍 Strategic Analysis

  • Value Chain Analysis
  • Porter's Five Forces
  • PESTLE Analysis
  • Pricing Trends
  • Supply-Demand Analysis

🚀 Future Outlook

  • Technology Landscape
  • Regulatory Landscape
  • Investment & Funding Landscape
  • Emerging Opportunities
  • Future Market Outlook

Have a question about this report or need a custom scope?

Request Customization
License

Select License Type

Single User
US$ 4,250
Buy Now
Corporate User
US$ 6,150
Buy Now

Want this data scoped to your exact question?

Tell us the segments, regions, or competitors you need answered — an analyst will confirm scope before any custom work starts.

Talk to an Analyst →